New drug combo aims to fight blood cancer with fewer nerve side effects
NCT ID NCT02441686
Summary
This study tested a combination of three medications (lenalidomide, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma, a blood cancer. Researchers wanted to see if giving bortezomib as an injection under the skin instead of into a vein would reduce nerve damage, a common side effect, while still effectively treating the cancer. The trial involved 46 participants and measured how well the treatment worked and what side effects occurred.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Eastern Maine Medical Center
Brewer, Maine, 04412, United States
-
Hematology Oncology of Northern New Jersey
Morristown, New Jersey, 07962, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02114, United States
-
Virgina Piper Cancer Institute
Minneapolis, Minnesota, 55407, United States
-
Virginia Piper Cancer Institute
Coon Rapids, Minnesota, 55433, United States
Conditions
Explore the condition pages connected to this study.